Letter from the Editor-in-Chief: Growth of the Journal.
Letter from the Editor-in-Chief: Growth of the Journal.
复制标题
主编的来信：期刊的成长。
DOI：
10.1007/s13311-019-00783-8
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Mouradian,MMaral
中科院分区：
文献类型：
--
作者：
Mouradian,MMaral
美国实验神经治疗学会的官方期刊《神经治疗学》自2004年创刊以来，经历了重大的发展和变革。它最初是一本综述杂志，每一期都有受邀的批评性评论，重点是与神经疾病的先进疗法相关的主题。2011年，除专题评论外，《华尔街日报》还开始发表与其使命有关的非应邀原创研究文章。自从我在2014年担任总编辑以来，提交的稿件数量增加了两倍多，发表的研究论文数量增加了四倍。2016年，我们还在每一期杂志上增加了《当前观点》的新功能。这些受邀的手稿提供了一个发布关键意见领袖对当前神经治疗学热点问题的观点的平台。
Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics, has gone through major growth and transformation since its launch in 2004. It began as a review journal, with each issue consisting of invited critical reviews that focus on a theme related to advancing therapeutics for neurological disorders. In 2011, the Journal began publishing unsolicited original research articles relevant to its mission in addition to the thematic reviews. Since I assumed the role of Editor-in-Chief in 2014, the number of manuscript submissions has more than tripled, and the number of published research articles has quadrupled. In 2016, we also added the new feature of Current Perspectives to each issue. These invited manuscripts provide a platform for publishing points-of-view by key opinion leaders on current hot topics in neurologic therapeutics.